Generic Name and Formulations:
Tobramycin 0.3%, dexamethasone 0.1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for TOBRADEX:
Ocular inflammation associated with infection or risk thereof.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1–2 drops every 2hrs for 1st 24–48 hrs, then every 4–6 hrs. Reduce dose as condition improves; max 20mL for initial ℞.
Viral, fungal, or mycobacterial infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, intraocular pressure and cataracts in prolonged use. Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Aminoglycoside + steroid.
Local effects (eg, eye pain, eyelids pruritus, eyelid edema, conjunctival hyperemia or erythema), increased intraocular pressure, glaucoma, cataracts, corneal perforations, optic nerve damage, delayed wound healing, secondary infection.
Susp—2.5mL, 5mL, 10mL; Oint—3.5g
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure